ARCHIVES

Research teams link response to Iressa to mutations in EGF receptor.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

Nexavar Improves PFS In Phase III Trial

January 25, 2013

HHS Agency Says It Has No Jurisdiction And No Cause to Act on I-ELCAP Allegations

March 2, 2012

Organ Site Program Fate On Line, Gets Review Next Week

November 20, 1981

In Brief: NCI Authorization Should be $1.3 Billion, Humphrey Tells Kennedy; GOG Gets New Life

March 3, 1978

NIH Clinical Trials Committee Adopts Recommendations For Safety Monitoring

June 22, 1979

Racial Differences In Survival Increase According To Stage

August 31, 2007